These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38168194)

  • 1. Saturation genome editing-based functional evaluation and clinical classification of BRCA2 single nucleotide variants.
    Huang H; Hu C; Na J; Hart SN; Gnanaolivu RD; Abozaid M; Rao T; Tecleab YA; Pesaran T; Lyra PCM; Karam R; Yadav S; Domchek SM; de la Hoya M; Robson M; Mehine M; Bandlamudi C; Mandelker D; Monteiro ANA; Boddicker N; Chen W; Richardson ME; Couch FJ
    bioRxiv; 2023 Dec; ():. PubMed ID: 38168194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain.
    Hu C; Huang H; Na J; Lumby C; Abozaid M; Holdren MA; Rao TJ; Karam R; Pesaran T; Weyandt JD; Csuy CM; Seelaus CA; Young CC; Fulk K; Heidari Z; Morais Lyra PC; Couch RE; Persons B; Polley EC; Gnanaolivu RD; Boddicker NJ; Monteiro ANA; Yadav S; Domchek SM; Richardson ME; Couch FJ
    Am J Hum Genet; 2024 Mar; 111(3):584-593. PubMed ID: 38417439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
    Hu C; Susswein LR; Roberts ME; Yang H; Marshall ML; Hiraki S; Berkofsky-Fessler W; Gupta S; Shen W; Dunn CA; Huang H; Na J; Domchek SM; Yadav S; Monteiro ANA; Polley EC; Hart SN; Hruska KS; Couch FJ
    Clin Cancer Res; 2022 Sep; 28(17):3742-3751. PubMed ID: 35736817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance.
    Richardson ME; Hu C; Lee KY; LaDuca H; Fulk K; Durda KM; Deckman AM; Goldgar DE; Monteiro ANA; Gnanaolivu R; Hart SN; Polley EC; Chao E; Pesaran T; Couch FJ
    Am J Hum Genet; 2021 Mar; 108(3):458-468. PubMed ID: 33609447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
    Billaud A; Chevalier LM; Augereau P; Frenel JS; Passot C; Campone M; Morel A
    Genome Med; 2021 Nov; 13(1):174. PubMed ID: 34749799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic misclassification of missense variants in BRCA1 and BRCA2 "coldspots".
    Dines JN; Shirts BH; Slavin TP; Walsh T; King MC; Fowler DM; Pritchard CC
    Genet Med; 2020 May; 22(5):825-830. PubMed ID: 31911673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saturation genome editing of 11 codons and exon 13 of BRCA2 coupled with chemotherapeutic drug response accurately determines pathogenicity of variants.
    Sahu S; Sullivan TL; Mitrophanov AY; Galloux M; Nousome D; Southon E; Caylor D; Mishra AP; Evans CN; Clapp ME; Burkett S; Malys T; Chari R; Biswas K; Sharan SK
    PLoS Genet; 2023 Sep; 19(9):e1010940. PubMed ID: 37713444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules.
    Jimenez-Sainz J; Jensen RB
    Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.
    Guidugli L; Pankratz VS; Singh N; Thompson J; Erding CA; Engel C; Schmutzler R; Domchek S; Nathanson K; Radice P; Singer C; Tonin PN; Lindor NM; Goldgar DE; Couch FJ
    Cancer Res; 2013 Jan; 73(1):265-75. PubMed ID: 23108138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair.
    Jimenez-Sainz J; Mathew J; Moore G; Lahiri S; Garbarino J; Eder JP; Rothenberg E; Jensen RB
    Elife; 2022 Sep; 11():. PubMed ID: 36098506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Repair Function Scores for 2172 Variants in the BRCA1 Amino-Terminus.
    Diabate M; Islam MM; Nagy G; Banerjee T; Dhar S; Smith N; Adamovich AI; Starita LM; Parvin JD
    bioRxiv; 2023 Apr; ():. PubMed ID: 37090572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline Missense Variants in
    Golubeva VA; Nepomuceno TC; Monteiro ANA
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31013702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel.
    Parsons MT; de la Hoya M; Richardson ME; Tudini E; Anderson M; Berkofsky-Fessler W; Caputo SM; Chan RC; Cline MS; Feng BJ; Fortuno C; Gomez-Garcia E; Hadler J; Hiraki S; Holdren M; Houdayer C; Hruska K; James P; Karam R; Leong HS; Martins A; Mensenkamp AR; Monteiro AN; Nathan V; O'Connor R; Pedersen IS; Pesaran T; Radice P; Schmidt G; Southey M; Tavtigian S; Thompson BA; Toland AE; Turnbull C; Vogel MJ; Weyandt J; Wiggins GAR; Zec L; Couch FJ; Walker LC; Vreeswijk MPG; Goldgar DE; Spurdle AB
    Am J Hum Genet; 2024 Sep; 111(9):2044-2058. PubMed ID: 39142283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Validated Functional Analysis of Partner and Localizer of BRCA2 Missense Variants for Use in Clinical Variant Interpretation.
    Brnich SE; Arteaga EC; Wang Y; Tan X; Berg JS
    J Mol Diagn; 2021 Jul; 23(7):847-864. PubMed ID: 33964450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate classification of BRCA1 variants with saturation genome editing.
    Findlay GM; Daza RM; Martin B; Zhang MD; Leith AP; Gasperini M; Janizek JD; Huang X; Starita LM; Shendure J
    Nature; 2018 Oct; 562(7726):217-222. PubMed ID: 30209399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction.
    Caleca L; Catucci I; Figlioli G; De Cecco L; Pesaran T; Ward M; Volorio S; Falanga A; Marchetti M; Iascone M; Tondini C; Zambelli A; Azzollini J; Manoukian S; Radice P; Peterlongo P
    Front Oncol; 2018; 8():480. PubMed ID: 30410870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.
    Guidugli L; Shimelis H; Masica DL; Pankratz VS; Lipton GB; Singh N; Hu C; Monteiro ANA; Lindor NM; Goldgar DE; Karchin R; Iversen ES; Couch FJ
    Am J Hum Genet; 2018 Feb; 102(2):233-248. PubMed ID: 29394989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specifications of the ACMG/AMP Variant Classification Guidelines for Germline
    Hatton JN; Frone MN; Cox HC; Crowley SB; Hiraki S; Yokoyama NN; Abul-Husn NS; Amatruda JF; Anderson MJ; Bofill-De Ros X; Carr AG; Chao EC; Chen KS; Gu S; Higgs C; Machado J; Ritter D; Schultz KA; Soper ER; Wu MK; Mester JL; Kim J; Foulkes WD; Witkowski L; Stewart DR
    Hum Mutat; 2023; 2023():. PubMed ID: 38084291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
    So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
    Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.